New drugs from companies Eli Lilly and Novo Nordisk have become very popular for weight-loss. These medicines are effective, but their high cost makes them difficult for many people to afford. The list price can be over $1,000 a month.
For many Americans, this price is a major barrier. This is especially true for people with government insurance like Medicare or Medicaid. Patients who must pay for the medicine themselves also face this financial challenge.
To solve this problem, President Trump announced a new agreement with the two drug companies. The goal was to make these important treatments available to more people who need them. The deal focuses on lowering the price for specific groups of patients.
Under the new plan, the cost for these drugs could drop to as little as $149 for a month's supply for certain doses. This significant price reduction is aimed at Medicare and Medicaid patients, as well as those paying out-of-pocket.
This change means millions of Americans might soon have access to medication that was previously out of reach. The agreement is a big step toward making these treatments more common and accessible across the country.